Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Valuation techniques [[electronic resource] ] : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss
| Valuation techniques [[electronic resource] ] : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss |
| Autore | Larrabee David T |
| Edizione | [1st edition] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2013 |
| Descrizione fisica | 1 online resource (624 p.) |
| Disciplina | 332.63/221 |
| Altri autori (Persone) | VossJason Apollo |
| Collana | CFA Institute investment perspectives series |
| Soggetto topico |
Corporations - Valuation
Investment analysis |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-118-41760-7
1-283-70025-5 1-118-42179-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Valuation Techniques: Discounted Cash Flow, Earnings Quality, Measures of Value Added, and Real Options; Copyright; Contents; Foreword; Introduction; Part I: Valuation Perspectives: Then and Now; Chapter 1: Two Illustrative Approaches to Formula Valuations of Common Stocks; Notes; Chapter 2: Seeking a Margin of Safety and Valuation; Two Basic Investment Goals; The Price of Money is Fake; The Future is Uncertain; Dealing with Macro Risk; Owning an Enterprise Preserves Purchasing Power; Seek a Margin of Safety; Valuation; Business Model Erosion; Focus on Assets, Not on Residual Equity
Management Flexibility to Look Different; Conclusion; Question and Answer Session; Note; Part II: Valuation Methodologies; Chapter 3: Company Performance and Measures of Value Added; Foreword; Acknowledgments; Introduction; How Value Is Created; Relating New Performance Methods to Capital-Budgeting Techniques; Summary; Traditional Measures of Performance; Return-on-Investment Ratios; Tobin's; Summary; Measures of Value Added; Economic Profit; Market Value Added; Reconciling Economic Value Added with Market Value Added; Challenges in Applying Value-Added Measures; Holt's Cfroi; Summary Comparison of Alternative Performance MeasuresThe Sample; The Variables; Empirical Results; Summary; Conclusions; Appendix 3A: The Firm's Cost Of Capital; Cost of Debt; Cost of Preferred Stock; The Cost of Common Equity; Weighted-Average Cost of Capital; Issues in Calculating a WACC; Appendix 3B: Net Present Value and Internal Rate of Return; Glossary; Notes; References; Chapter 4: The Affordable Dividend Approach to Equity Valuation; Affordable Dividends; Affordable vs. Conventional dividends; Significance of Difference; Book Value vs. Economic Value weights; Conclusion; Notes Chapter 5: Discounted-Cash-Flow Approach to Valuation The DCF Formula; Estimation of Cash Flows; Discount Rate; Definition; External Factors; Internal Factors; Components; Terminal Value; Conclusion; Question and Answer Section; Note; Chapter 6: Equity Securities Analysis Case Study: Merck & Company; Recent Annual Reports; Strategic Objectives; Structural Reorganization; Position on Health Care Reform; Outlook for the Future; Fundamentals of the U.S. Pharmaceutical Industry; Pricing and the Demand for Pharmaceuticals; Consolidation and Joint Ventures; Marketing Trends International Competition The U.S. Political/Regulatory Environment; Tasks to be Completed; Appendix 6A: Merck & Company Financial Data; Appendix 6B: Statistical Data: Pharmaceutical Industry; Appendix 6C: Competitive Strategy Analysis Framework; Appendix 6D: Review of the Dupont Financial Ratio Analysis Method; Appendix 6E: Selected Valuation Methods; Single-Stage Constant-Growth DCF Model; Multistage DCF Model; H-Model; Financial Ratios Approaches; Guideline Answers: The Merck Case; The Current Issues Involved in Marketing Pharmaceuticals The Competitive Structure of the U.S. Pharmaceutical Industry |
| Record Nr. | UNINA-9910461795603321 |
Larrabee David T
|
||
| Hoboken, N.J., : John Wiley & Sons, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Valuation techniques [[electronic resource] ] : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss
| Valuation techniques [[electronic resource] ] : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss |
| Autore | Larrabee David T |
| Edizione | [1st edition] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2013 |
| Descrizione fisica | 1 online resource (624 p.) |
| Disciplina | 332.63/221 |
| Altri autori (Persone) | VossJason Apollo |
| Collana | CFA Institute investment perspectives series |
| Soggetto topico |
Corporations - Valuation
Investment analysis |
| ISBN |
1-118-41760-7
1-283-70025-5 1-118-42179-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Valuation Techniques: Discounted Cash Flow, Earnings Quality, Measures of Value Added, and Real Options; Copyright; Contents; Foreword; Introduction; Part I: Valuation Perspectives: Then and Now; Chapter 1: Two Illustrative Approaches to Formula Valuations of Common Stocks; Notes; Chapter 2: Seeking a Margin of Safety and Valuation; Two Basic Investment Goals; The Price of Money is Fake; The Future is Uncertain; Dealing with Macro Risk; Owning an Enterprise Preserves Purchasing Power; Seek a Margin of Safety; Valuation; Business Model Erosion; Focus on Assets, Not on Residual Equity
Management Flexibility to Look Different; Conclusion; Question and Answer Session; Note; Part II: Valuation Methodologies; Chapter 3: Company Performance and Measures of Value Added; Foreword; Acknowledgments; Introduction; How Value Is Created; Relating New Performance Methods to Capital-Budgeting Techniques; Summary; Traditional Measures of Performance; Return-on-Investment Ratios; Tobin's; Summary; Measures of Value Added; Economic Profit; Market Value Added; Reconciling Economic Value Added with Market Value Added; Challenges in Applying Value-Added Measures; Holt's Cfroi; Summary Comparison of Alternative Performance MeasuresThe Sample; The Variables; Empirical Results; Summary; Conclusions; Appendix 3A: The Firm's Cost Of Capital; Cost of Debt; Cost of Preferred Stock; The Cost of Common Equity; Weighted-Average Cost of Capital; Issues in Calculating a WACC; Appendix 3B: Net Present Value and Internal Rate of Return; Glossary; Notes; References; Chapter 4: The Affordable Dividend Approach to Equity Valuation; Affordable Dividends; Affordable vs. Conventional dividends; Significance of Difference; Book Value vs. Economic Value weights; Conclusion; Notes Chapter 5: Discounted-Cash-Flow Approach to Valuation The DCF Formula; Estimation of Cash Flows; Discount Rate; Definition; External Factors; Internal Factors; Components; Terminal Value; Conclusion; Question and Answer Section; Note; Chapter 6: Equity Securities Analysis Case Study: Merck & Company; Recent Annual Reports; Strategic Objectives; Structural Reorganization; Position on Health Care Reform; Outlook for the Future; Fundamentals of the U.S. Pharmaceutical Industry; Pricing and the Demand for Pharmaceuticals; Consolidation and Joint Ventures; Marketing Trends International Competition The U.S. Political/Regulatory Environment; Tasks to be Completed; Appendix 6A: Merck & Company Financial Data; Appendix 6B: Statistical Data: Pharmaceutical Industry; Appendix 6C: Competitive Strategy Analysis Framework; Appendix 6D: Review of the Dupont Financial Ratio Analysis Method; Appendix 6E: Selected Valuation Methods; Single-Stage Constant-Growth DCF Model; Multistage DCF Model; H-Model; Financial Ratios Approaches; Guideline Answers: The Merck Case; The Current Issues Involved in Marketing Pharmaceuticals The Competitive Structure of the U.S. Pharmaceutical Industry |
| Record Nr. | UNINA-9910785921503321 |
|
Larrabee David T
|
||
| Hoboken, N.J., : John Wiley & Sons, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Valuation techniques : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss
| Valuation techniques : discounted cash flow, earnings quality, measures of value added, and real options / / David T. Larrabee and Jason A. Voss |
| Autore | Larrabee David T |
| Edizione | [1st edition] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2013 |
| Descrizione fisica | 1 online resource (624 p.) |
| Disciplina | 332.63/221 |
| Altri autori (Persone) | VossJason Apollo |
| Collana |
CFA Institute investment series
CFA Institute investment perspectives series |
| Soggetto topico |
Corporations - Valuation
Investment analysis |
| ISBN |
1-118-41760-7
1-283-70025-5 1-118-42179-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Valuation Techniques: Discounted Cash Flow, Earnings Quality, Measures of Value Added, and Real Options; Copyright; Contents; Foreword; Introduction; Part I: Valuation Perspectives: Then and Now; Chapter 1: Two Illustrative Approaches to Formula Valuations of Common Stocks; Notes; Chapter 2: Seeking a Margin of Safety and Valuation; Two Basic Investment Goals; The Price of Money is Fake; The Future is Uncertain; Dealing with Macro Risk; Owning an Enterprise Preserves Purchasing Power; Seek a Margin of Safety; Valuation; Business Model Erosion; Focus on Assets, Not on Residual Equity
Management Flexibility to Look Different; Conclusion; Question and Answer Session; Note; Part II: Valuation Methodologies; Chapter 3: Company Performance and Measures of Value Added; Foreword; Acknowledgments; Introduction; How Value Is Created; Relating New Performance Methods to Capital-Budgeting Techniques; Summary; Traditional Measures of Performance; Return-on-Investment Ratios; Tobin's; Summary; Measures of Value Added; Economic Profit; Market Value Added; Reconciling Economic Value Added with Market Value Added; Challenges in Applying Value-Added Measures; Holt's Cfroi; Summary Comparison of Alternative Performance MeasuresThe Sample; The Variables; Empirical Results; Summary; Conclusions; Appendix 3A: The Firm's Cost Of Capital; Cost of Debt; Cost of Preferred Stock; The Cost of Common Equity; Weighted-Average Cost of Capital; Issues in Calculating a WACC; Appendix 3B: Net Present Value and Internal Rate of Return; Glossary; Notes; References; Chapter 4: The Affordable Dividend Approach to Equity Valuation; Affordable Dividends; Affordable vs. Conventional dividends; Significance of Difference; Book Value vs. Economic Value weights; Conclusion; Notes Chapter 5: Discounted-Cash-Flow Approach to Valuation The DCF Formula; Estimation of Cash Flows; Discount Rate; Definition; External Factors; Internal Factors; Components; Terminal Value; Conclusion; Question and Answer Section; Note; Chapter 6: Equity Securities Analysis Case Study: Merck & Company; Recent Annual Reports; Strategic Objectives; Structural Reorganization; Position on Health Care Reform; Outlook for the Future; Fundamentals of the U.S. Pharmaceutical Industry; Pricing and the Demand for Pharmaceuticals; Consolidation and Joint Ventures; Marketing Trends International Competition The U.S. Political/Regulatory Environment; Tasks to be Completed; Appendix 6A: Merck & Company Financial Data; Appendix 6B: Statistical Data: Pharmaceutical Industry; Appendix 6C: Competitive Strategy Analysis Framework; Appendix 6D: Review of the Dupont Financial Ratio Analysis Method; Appendix 6E: Selected Valuation Methods; Single-Stage Constant-Growth DCF Model; Multistage DCF Model; H-Model; Financial Ratios Approaches; Guideline Answers: The Merck Case; The Current Issues Involved in Marketing Pharmaceuticals The Competitive Structure of the U.S. Pharmaceutical Industry |
| Record Nr. | UNINA-9910807230903321 |
|
Larrabee David T
|
||
| Hoboken, N.J., : John Wiley & Sons, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||